

Ref. No.P-66/2024-25/29
August 12, 2024

The Relationship Manager,
Department of Corporate Relations
BSE Limited,
P.J. Towers, Dalal Street
Fort, MUMBAI – 400 001

Subject: Outcome of Board Meeting held on Monday, 12th August, 2024

Pursuant to Regulations 30 & 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (Listing Regulations), , we wish to inform you that the Board of Directors of the Company at its Meeting held today i.e. 12th August, 2024, has inter-alia, considered and approved the following:

1. Financial results:

Unaudited Standalone and Consolidated Financial Results of the Company for the quarter ended on 30th June 2024. The same has also been reviewed by the Audit Committee in its meeting held today.

Further, Baheti & Co., Statutory Auditors of the Company have carried out the Limited Review of the Unaudited Standalone and Consolidated Financial Results for the quarter ended 30th June 2024 and the Board has also taken on record their Limited Review Reports on the said Financial Results.

A copy of the Financial Results along with Limited Review Report for the quarter ended 30th June, 2024, as required under Regulation 33 of the Listing Regulations, is attached.

3. Re-appointment of Mrs. Mithla Dubey (DIN: 03597415) aged 77 years, as a Non-Executive Director of the Company liable to retire by rotation, for a period of 5(five) years with effect from 27th March, 2025 to 26th March, 2030, subject to approval of shareholders in the ensuing Annual General Meeting.

The details as required under Regulation 30 of the SEBI Listing Regulations read with the SEBI Circular No. SEBI/HO/CFD/CFD-PoD1/P/CIR/2023/123 dated 13th July 2023 are enclosed herewith as Annexure-A.

4. Appointment of Mr. Rajesh Dubey (DIN 10738590) as an Independent Director of the Company to hold office for a term of five years, w.e.f. September 25, 2024 upto September 24, 2029 subject to approval of shareholders in the ensuing Annual General Meeting.

The details as required under Regulation 30 of the SEBI Listing Regulations read with the SEBI Circular No. SEBI/HO/CFD/CFD-PoD1/P/CIR/2023/123 dated 13th July 2023 are enclosed herewith as Annexure-A.

5. Continuation of Mr. Abdul Moin Khan (DIN: 07918067) as an Independent Director of the Company for the second term of 5years, i.e. from 26th September 2022 upto 25th September 2027, who will attain the age of seventy five (75) years on January 1,2025 subject to approval of Shareholders of the Company at the ensuing Annual General Meeting

The details as required under Regulation 30 of the SEBI Listing Regulations read with the SEBI Circular No. SEBI/HO/CFD/CFD-PoD1/P/CIR/2023/123 dated 13th July 2023 are enclosed herewith as Annexure-A.

6. Appointment of M/s Sanjay Kasliwal & Associates, Cost Accountants & Social Auditor, Bhopal as Cost Auditor of the Company for the FY 2024-25;

The said appointment of M/s. Sanjay Kasliwal & Associates is in compliance with Section 141 and Section 148 of the Companies Act, 2013 and other applicable provisions, if any, read with Companies (Cost Records and Audit) Rules, 2014. The remuneration payable to M/s Sanjay Kasliwal & Associates shall be placed before the shareholders for ratification at the ensuing Annual General Meeting.

The details as required under Regulation 30 of the SEBI Listing Regulations read with the SEBI Circular No. SEBI/HO/CFD/CFD-PoD1/P/CIR/2023/123 dated 13th July 2023 are enclosed herewith as Annexure-A.

The Meeting of the Board of Directors held today commenced at 1:30 P.M. and concluded at 3:30 P.M.

Kindly take the same on your records.


Thanking You,
For 3B BlackBio Dx Limited (Formerly, Kilpest India Limited)

Nikhil Kuber Dubey
Whole Time Director
DIN: 00538049

Encl: As above




Name	Mrs. Mithla Dubey	Mr. Rajesh Dubey	Mr. Abdul Moin Khan	M/s.Sanjay Kasliwal & Associates
Reason for change viz. appointment, resignation, removal, death or otherwise	Re-appointment	Appointment	Re-appointment	Appointment
Date of appointment/ces sation (as applicable) & term of appointment	The Board of Directors of the Company at its meeting held today i.e. 12th August 2024 approved the re-appointment of Mrs. Mithla Dubey as a Non-Executive Director. The tenure of her reappointment will be for a period of 5 years w.e.f 27 th March, 2025 to 26 th March, 2030, which is subject to approval of the shareholders in the ensuing AGM	The Board of Directors of the Company at its meeting held today i.e. 12th August 2024 approved the appointment of Mr. Rajesh Dubey as a Independent Director. The tenure of his appointment will be for a period of 5 years w.e.f 25th September 2024 up to 26th September 2029, which is subject to approval of the shareholders in the ensuing AGM	The Board of Directors of the Company at its meeting held today i.e. 12th August 2024 approved his Continuation as an Independent Director of the Company for the second term of 5years, i.e. from 26 th September 2022 upto 25 th September 2027, who will attain the age of seventy five (75) years on January 1,2025 subject to approval of Shareholders at the ensuing Annual General Meeting	Appointed as Cost Auditor for FY 2024-25 at the Board meeting held on 12th August, 2024, to issue Cost Audit Report as per the provisions of the Companies Act, 2013
Brief Profile	As per the applicable provisions of the Companies Act, 2013 and amended SEBI (Listing Regulations) the Company should have at least one woman director. In	Mr.Rajesh Dubey is a post graduate from DAV, Indore .He has over thirty (30) years' experience of sales and marketing in	Mr.Abdul Moin Khan aged 74;(Rtd.Deputy Commissioner) has worked in important positions in M.P. State Government. Starting his	M/s. Sanjay Kasliwal & Associates, Cost Accountants & Social Auditor, Bhopal (Firm Regd. No. 100888) has experience and expertise in Cost



	<p>lieu to this, Mrs. Mithla Dubey, aged 77 years was appointed. She is generally associated with the Company as Director promoter and is actively involved in the social areas of the society.</p>	<p>pharma industries. He was associated in past with leading pharmaceutical companies like Micro Labs Limited, Bangalore and Sterling labs, Bangalore. His appointment as an independent director will be a valuable addition for the company.</p>	<p>career as Rural Development Officer with his lustrous track records, he was elevated to the post of special secretary to Honorable health Minister, Govt. of M.P. where he was nodal in policy making, implementation , and solving all Health Department related matters. After that he worked as a Deputy Commissioner Rural Development, Bhopal Division (comprising of eight districts) where he was nodal in developing policy for Rural Development for Bhopal Division, and its policy implementation . He has good experience in Governance issue in Health and Development sector.</p>	<p>Audit over the years. The firm also provides Guidance for Maintenance of Cost Accounting Records as prescribed under the Companies (Cost Records and Audit) Rules, 2014 and certification as regards maintenance of Cost Records by the Company.</p>
--	---	--	--	---

For 3B BlackBio Dx Limited



Director

3B BLACKBIO DX LIMITED
(Formerly, KILPEST INDIA LIMITED)
REGD.OFFICE: 7-C, INDUSTRIAL AREA, GOVINDPURA, BHOPAL-462 023
CIN:L24211MP1972PLC001131

Statement of Standalone Unaudited Financial Results For The Quarter Ended 30-06-2024

(Rs. In Lakhs)

S.No.	PARTICULARS	QUARTER ENDED			YEAR ENDED
		30-06-2024 (Unaudited)	31-03-2024 (Audited)	30-06-2023 (Unaudited)	31-03-2024 (Audited)
I	Revenue from operations	1750.69	2198.59	1321.31	7072.45
II	Other income	367.78	414.65	295.98	1231.80
III	Total Income (I + II)	2118.47	2613.24	1617.30	8304.25
IV	Expenses:				
	Cost of materials consumed	497.34	551.73	408.59	1981.13
	Purchases of Stock-in-Trade	0.00	0	0.00	0.00
	Changes in inventories of finished goods work-in-	-45.77	1.35	-25.66	34.27
	Employee benefits expenses	128.80	141.37	107.71	514.44
	Finance costs	0.62	3.93	1.71	11.38
	Depreciation and amortization expense	22.00	26.85	17.75	86.85
	Other expenses	136.22	488.41	161.83	1031.73
	Total expenses (IV)	739.21	1213.64	671.93	3659.80
V	Profit/(loss) before exceptional items and tax (III - IV)	1379.26	1399.60	945.37	4644.45
VI	Exceptional items	0.00	0.00	0.00	0.00
VII	Profit before tax (V - VI)	1379.26	1399.60	945.37	4644.45
VIII	Tax expense:				
	(1) Current tax	305.97	354.84	198.45	1084.07
	(2) Deferred tax	0.00	139.03	0.00	139.03
IX	Profit (Loss) for the period (VII-VIII)	1073.29	905.73	746.92	3421.35
X	Other Comprehensive Income/(loss)	0.00	0.00	0.00	0.00
XI	Total Comprehensive Income for the period (IX+X)	1073.29	905.73	746.92	3421.35
XII	Paid-up Equity Share capital	856.84	856.84	856.64	856.84
XIII	Reserve excluding Revaluation Reserves as per balance sheet of previous year	21921.24	18860.28	16264.62	18860.28
XIV	Earnings per equity share:				
	(1) Basic	12.53	10.57	8.72	39.93
	(2) Diluted	12.53	10.57	8.72	39.93

FOR AND ON BEHALF OF THE BOARD




NIKHIL KUBER DUBEY
WHOLE TIME DIRECTOR
DIN:00538049

PLACE: BHOPAL
DATE : 12/08/2024




BAHETI & CO.
CHARTERED ACCOUNTANTS
24, M.P. NAGAR ZONE II
BHOPAL 462011
2763141,4251535


Independent Auditor's Review Report on the Quarterly Unaudited Standalone Financial Results of the Company Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended

Review Report to
The Board of Directors of
3B BlackBio Dx Limited (Formerly, Kilpest India Limited)

1. We have reviewed the accompanying statement of unaudited standalone financial results of 3B BlackBio Dx Limited (Formerly, Kilpest India Limited) (the "Company") for the quarter ended June 30, 2024 (the "Statement") attached herewith, being submitted by the Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (the "Listing Regulations").
2. The Company's Management is responsible for the preparation of the Statement in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, (Ind AS 34) "Interim Financial Reporting" prescribed under Section 133 of the Companies Act, 2013 as amended, read with relevant rules issued there under and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. The Statement has been approved by the Company's Board of Directors. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.
4. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standards ('Ind AS') specified under Section 133 of the Companies Act, 2013 as amended, read with relevant rules issued there under and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of the Listing Regulations, including the manner in which it is to be disclosed, or that it contains any material misstatement

For BAHETI & CO.
Chartered Accountants
(Firm Registration No 006287C)


(DEEPAK BAHETI)
Partner



Membership No: 075063

Place: Bhopal
Date: 12/08/2024

UDIN: 24075063BKBIAO5807



NOTES ON STANDALONE UN-AUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED 30th
JUNE, 2024

1. The above results are as per Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 as amended and have been taken on record by the Board of Directors at its meeting held on August 12, 2024 after being reviewed by the Audit Committee.
2. The Company's Agrochemical Business is seasonal in nature and the performance can be impacted by weather conditions and cropping pattern.
3. These financial results have been prepared In accordance with the requirements of Indian Accounting Standards (Ind AS) as prescribed under section 133 of Companies Act, 2013 read with Companies (Indian Accounting Standards) Rules, 2015 as amended.
4. The figures for the quarter ended March 31, 2024 are the balancing figures between the audited figures in respect of full financial year and the unaudited published year to date figures for the nine months ended December 31, 2023, being the date of the end of the third quarter of the financial year, which were subjected to limited review.
5. All the figures of financials have been rounded off to nearest lakh in rupees.
6. Previous period/Year figures have been regrouped / rearranged, wherever deemed necessary.
7. The results of the company are available for investors at www.kilpest.com and www.bseindia.com.

Limited Review:

The Limited Review, as required under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 as amended, has been completed and the related Report shall be forwarded to the Stock Exchanges. This Report does not have any impact on the above "Results and Notes" for the quarter ended June 30, 2024 which needs to be explained.

FOR AND ON BEHALF OF THE BOARD



NIKHIL KUBER DUBEY
WHOLE TIME DIRECTOR
DIN: 00538049

PLACE: BHOPAL
DATE: 12/08/2024



3B BLACKBIO DX LIMITED
(Formerly, KILPEST INDIA LIMITED)
REGD.OFFICE: 7-C, INDUSTRIAL AREA, GOVINDPURA, BHOPAL-462 023
CIN:L24211MP1972PLC001131

Statement of Consolidated Unaudited Financial Results For The Quarter Ended 30-06-2024

(Rs. In Lakhs)

S.No.	PARTICULARS	QUARTER ENDED			YEAR ENDED
		30-06-2024	31-03-2024	30-06-2023	31-03-2024
		(Unaudited)	(Audited)	(Unaudited)	(Audited)
I	Revenue from operations	1943.40	2299.80	1428.23	7412.47
II	Other income	369.10	419.44	296.09	1253.26
III	Total Income (I + II)	2312.50	2719.24	1724.32	8665.73
IV	Expenses:				
	Cost of materials consumed	511.98	448.26	420.01	1981.13
	Purchases of Stock-in-Trade	0.00	173.28	0	173.28
	Changes in inventories of finished goods work-in-progress and Stock-in-Trade	-45.77	-3.12	-25.66	29.80
	Employee benefits expenses	162.15	161.41	144.09	650.24
	Finance costs	0.62	4.13	1.71	12.44
	Depreciation and amortization expense	26.80	30.40	19.33	105.71
	Other expenses	220.99	531.98	245.76	1279.91
	Total expenses (IV)	876.77	1346.34	805.24	4232.51
V	Profit/(loss) before exceptional items and tax (III - IV)	1435.73	1372.9	919.08	4433.22
VI	Exceptional items	0.00	0.00	0	0.00
VII	Profit before tax (V - VI)	1435.73	1372.9	919.08	4433.22
VIII	Tax expense:				
	(1) Current tax	305.97	354.84	198.45	1084.07
	(2) Deferred tax	0.00	139.03	0	139.03
IX	Profit (Loss) for the period (VII-VIII)	1129.76	879.03	720.63	3210.12
	Profit or loss, attributable to owners of parent	1112.82	887.04	728.51	3273.49
	Total profit or loss, attributable to non-controlling interests	16.94	-8.01	-7.88	-63.37
X	Other Comprehensive Income/(loss)	0.00	0.00	0	0
XI	Total Comprehensive Income for the period (IX+X)	1129.76	879.03	720.63	3210.12
	Profit or loss, attributable to owners of parent	1112.82	887.04	728.51	3273.49
	Total profit or loss, attributable to non-controlling interests	16.94	-8.01	-7.88	-63.37
XII	Paid-up Equity Share capital	856.84	856.84	856.84	856.84
XIII	Reserve excluding Revaluation Reserves as per balance sheet of previous year	21690.58	18841.90	16267.62	18841.90
XIV	Earnings per equity share:				
	(1) Basic	13.19	10.26	8.41	37.46
	(2) Diluted	13.19	10.26	8.41	37.46

FOR AND ON BEHALF OF THE BOARD

NIKHIL KUBER DUBEY
WHOLE TIME DIRECTOR
DIN:00538049

PLACE: BHOPAL
DATE : 12/08/2024



BAHETI & CO.
CHARTERED ACCOUNTANTS
24, M.P. NAGAR ZONE II
BHOPAL 462011
2763141, 4251535

Independent Auditor's Review Report on the Quarterly Unaudited Consolidated Financial Results of the Company Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended

Review Report to
The Board of Directors of
3B BlackBioDx Limited (Formerly, Kilpest India Limited)

We have reviewed the accompanying Statement of unaudited consolidated financial results of 3B BlackBioDx Limited (Formerly, Kilpest India Limited) ('hereinafter referred to as 'the Holding Company'), its subsidiary (the Holding Company and its subsidiaries together referred to as "the Group") for the quarter ended 30 June 2024 ('the Statement'), being submitted by the Holding Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ('Listing Regulations').

The Holding Company's Management is responsible for the preparation of the Statement in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, (Ind AS 34) "Interim Financial Reporting" prescribed under Section 133 of the Companies Act, 2013 as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. The Statement has been approved by the Holding Company's Board of Directors. Our responsibility is to express a conclusion on the Statement based on our review.

We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.



We also performed procedures in accordance with the Master Circular issued by the Securities and Exchange Board of India under Regulation 33(8) of the Listing Regulations, to the extent applicable.

The Statement includes the results of the following entities:

- i. 3B BlackBioDx Limited (Formerly, Kilpest India Limited, Holding)
- ii. TRUPCR Europe Limited (Subsidiary)


Based on our review conducted and procedures performed as stated in paragraph 3 above and based on the consideration of the review reports of other auditors as referred below, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with recognition and measurement principles laid down in the aforesaid Indian Accounting Standards ('Ind AS') specified under Section 133 of the Companies Act, 2013, as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of the Listing Regulations, including the manner in which it is to be disclosed, or that it contains any material misstatement.

The unaudited interim financial results and other unaudited financial information of these subsidiaries have not been reviewed by their auditor and have been approved and furnished to us by the Management and our conclusion on the Statement, in so far as it relates to the affairs of these subsidiaries, are based solely on such unaudited interim financial results and other unaudited financial information. According to the information and explanations given to us by the Management, these interim financial results are not material to the Group.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the Listing Regulations, including the manner in which it is to be disclosed, or that it contains any material misstatement.

Place: Bhopal
Date: 12/08/2024

For BAHETI & CO.
(FRN 006287C)
Chartered Accountants



(DEEPAK BAHETI)
Partner



Membership No.075063

UDIN 24075063BKBIAP7430



NOTES ON CONSOLIDATED UN-AUDITED FINANCIAL RESULT FOR THE QUARTER ENDED 30th JUNE, 2024

1. The above results are as per Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 as amended and have been taken on record by the Board of Directors at its meeting held on August 12, 2024 after being reviewed by the Audit Committee.
2. These financial results have been prepared in accordance with the requirements of Indian Accounting Standards (Ind AS) as prescribed under section 133 of Companies Act, 2013 read with Companies (Indian Accounting Standards) Rules, 2015 as amended;
3. The Company has two identified Reportable Business Segments namely Agrochemical and Molecular Diagnostic Kits (Health Care Sector)
4. The summarized figures for M/s 3B BLACKBIO DX LIMITED (FORMERLY, KILPEST INDIA LIMITED) (Both Agrochemicals and Diagnostic Division) as a standalone entity are:

PARTICULARS	QUARTER ENDED			YEAR ENDED
	30-06-2024	31-03-2024	30-06-2023	31-03-2024
	(unaudited)	(audited)	(unaudited)	(audited)
Total Income (Rs Lakhs)	2118.47	2613.24	1617.30	8304.25
Profit Before Tax (Rs Lakhs)	1379.26	1399.60	945.37	4644.45
Profit After Tax (Rs Lakhs)	1073.29	905.73	746.92	3421.35
Basic Earnings Per Share (Rs)	12.53	10.57	8.72	39.93

5. The figures for the quarter ended March 31, 2024 are the balancing figures between the audited figures in respect of full financial year and the unaudited published year to date figures for the nine months ended December 31, 2023, being the date of the end of the third quarter of the financial year, which were subjected to limited review.
6. The Consolidated Financials include the Financials of Subsidiary Company also.
7. All the figures of financials have been rounded off to nearest lakh in rupees.
8. Previous period/Year figures have been regrouped / rearranged, wherever deemed necessary.






3B BlackBio Dx Ltd.

(Formerly - Kilpest India Limited)

9. The Results of the Company are available for investors at www.kilpest.com and www.bseindia.com

Limited Review:

The Limited Review, as required under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 as amended, has been completed and the related Report shall be forwarded to the Stock Exchanges. This Report does not have any impact on the above "Results and Notes" for the quarter ended June 30, 2024 which needs to be explained

FOR AND ON BEHALF OF THE BOARD



NIKHIL KUBER DUBEY
WHOLE TIME DIRECTOR
DIN: 00538049

PLACE: BHOPAL
DATE: 12/08/2024

3B BLACKBIO DX LIMITED
(Formerly, KILPEST INDIA LIMITED)
REGD.OFFICE: 7-C, INDUSTRIAL AREA, GOVINDPURA, BHOPAL-462 023
CIN:L24211MP1972PLC001131


CONSOLIDATED SEGMENTWISE

REVENUE AND RESULTS

(Rs. In Lakhs)

	Quarter ended 30-06-2024 Unaudited	Quarter ended 31-03-2024 Audited	Quarter ended 30-06-2023 Unaudited	Year ended 31-03-2024 Audited
1 Segment Revenue				
(a) Agrochemicals	248.96	434.57	246.49	1368.51
(b) Diagnostic kits	1694.44	1906.48	1202.89	6085.21
Total income from operations (net)	1943.40	2341.05	1449.38	7453.72
2 Segment Results				
(a) Agrochemicals	-2.38	-17.07	33.94	187.47
(b) Diagnostic kits	1438.73	1394.10	886.86	4482.82
Total Segment Profit before Interest and Tax	1436.35	1377.03	920.80	4670.29
Less : Interest Expense				
(a) Agrochemicals	0.62	3.93	1.71	11.38
(b) Diagnostic kits	0.00	0.21	0.00	1.07
Profit before Tax	1435.73	1372.89	919.09	4657.84
3 Segment Assets				
(a) Agrochemicals	2851.40	2835.91	2846.54	2835.91
(b) Diagnostic kits	23823.88	22365.01	18976.45	22365.01
Total Segment Assets	26675.28	25200.92	21822.99	25200.92
4 Segment Liabilities				
(a) Agrochemicals	446.25	427.76	400.41	427.76
(b) Diagnostic kits	2190.98	1865.89	766.72	1865.89
Total Segment Liabilities	2637.23	2293.65	1167.13	2293.65
(a) Agrochemicals	2405.15	2408.15	2446.13	2408.15
(b) Diagnostic kits	21632.90	20499.12	18209.73	20499.12
5 Capital Employed	24038.05	22907.27	20655.86	22907.27

FOR AND ON BEHALF OF THE BOARD


NIKHIL KUBER DUBEY
WHOLE TIME DIRECTOR
DIN:00538049



PLACE: BHOPAL
DATE : 12/08/2024